News of Note—MaxiVAX, PATH and more


Here is some other vaccine news of note for the week.

> International nonprofit organization PATH updated its brand and website. Release

> Swiss biotech MaxiVAX received an FDA Investigational New Drug Application for MVX-ONCO-1 and appointed T. Scott Johnson, M.D., a founder of The Medicines Company, as its chairman. Release (PDF) | Release (PDF)

> Pfenex received a milestone payment from Merck after the pharma giant started a phase 3 trial of its 15-valent pneumococcal vaccine. The candidate is subject to a 2007 agreement between the companies that allowed Merck to utilize the biotech's technology platform. Release

> Agenus named Sunil Gupta, M.D., as VP of regulatory and pharmacovigilance and Anna Wijatyk, M.D., as VP of clinical development. Release